{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T04:03:26Z","timestamp":1720238606244},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ijcard.2016.02.140","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T04:06:33Z","timestamp":1456891593000},"page":"105-111","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris"],"prefix":"10.1016","volume":"211","author":[{"given":"Katerina","family":"Vellopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kourlaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Vardas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ijcard.2016.02.140_bb0005","first-page":"272","article-title":"Medical management of stable angina","volume":"55","author":"Andrikopoulos","year":"2014","journal-title":"Hell. J. Cardiol."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2016.02.140_bb0010","first-page":"S2","article-title":"Chronic stable angina guidelines \u2013 is there an emerging international consensus?","volume":"19","author":"Lopez-Sendon","year":"2012","journal-title":"Br. J. Cardiol."},{"issue":"12","key":"10.1016\/j.ijcard.2016.02.140_bb0015","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jama.295.12.1404","article-title":"Incidence and prognostic implications of stable angina pectoris among women and men","volume":"295","author":"Hemingway","year":"2006","journal-title":"JAMA"},{"issue":"11 Suppl.","key":"10.1016\/j.ijcard.2016.02.140_bb0020","first-page":"S339","article-title":"Estimating angina prevalence in a managed care population","volume":"10","author":"Zaher","year":"2004","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ijcard.2016.02.140_bb0025","first-page":"353","article-title":"Update on ranolazine in the management of angina","volume":"10","author":"Codolosa","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"issue":"12","key":"10.1016\/j.ijcard.2016.02.140_bb0030","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1161\/CIRCULATIONAHA.107.720953","article-title":"Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries","volume":"117","author":"Hemingway","year":"2008","journal-title":"Circulation"},{"issue":"11 Suppl","key":"10.1016\/j.ijcard.2016.02.140_bb0035","first-page":"S358","article-title":"Cost of illness of chronic angina","volume":"10","author":"Javitz","year":"2004","journal-title":"Am. J. Manag. Care"},{"issue":"10","key":"10.1016\/j.ijcard.2016.02.140_bb0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.acvd.2011.08.001","article-title":"Update on the medical treatment of stable angina","volume":"104","author":"Gayet","year":"2011","journal-title":"Arch. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/j.ijcard.2016.02.140_bb0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7861\/clinmedicine.13-1-63","article-title":"Pharmacological treatment of chronic stable angina pectoris","volume":"13","author":"Tarkin","year":"2013","journal-title":"Clin. Med."},{"issue":"38","key":"10.1016\/j.ijcard.2016.02.140_bb0050","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force","year":"2013","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.ijcard.2016.02.140_bb0055","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2016.02.140_bb0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-012-0005-z","article-title":"Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijcard.2016.02.140_bb0065","series-title":"European Public Assessment Report","author":"Agency","year":"2009"},{"issue":"8","key":"10.1016\/j.ijcard.2016.02.140_bb0070","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2016.02.140_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijcard.2016.02.140_bb0080","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"10.1016\/j.ijcard.2016.02.140_bb0085","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.ijcard.2016.02.140_bb0090","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ijcard.2016.02.140_bb0095","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1590\/S1984-82502011000200004","article-title":"Pharmacoeconomy: an indispensable tool for the rationalization of health costs","volume":"47","author":"Areda","year":"2014","journal-title":"Braz. J. Pharm. Sci."},{"key":"10.1016\/j.ijcard.2016.02.140_bb0100","author":"Centre for Reviews and Dissemination, U.o.Y."},{"issue":"10","key":"10.1016\/j.ijcard.2016.02.140_bb0105","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ijcard.2016.02.140_bb0110","doi-asserted-by":"crossref","first-page":"A323","DOI":"10.1016\/j.jval.2014.08.1429","article-title":"Cost-effectiveness of ranolazine for the treatment of angina pectoris in Russia","volume":"17","author":"Gorokhova","year":"2014","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.ijcard.2016.02.140_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18553\/jmcp.2003.9.1.53","article-title":"Examining the value and quality of health economic analyses: implications of utilizing the QHES","volume":"9","author":"Ofman","year":"2003","journal-title":"J. Manag. Care Pharm."},{"issue":"3","key":"10.1016\/j.ijcard.2016.02.140_bb0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1524-4733.2007.00255.x","article-title":"Reliability of two instruments for critical assessment of economic evaluations","volume":"11","author":"Au","year":"2008","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.ijcard.2016.02.140_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008861","article-title":"Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective","volume":"5","author":"Coleman","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ijcard.2016.02.140_bb0130","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12913-015-1228-y","article-title":"Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study","volume":"15","author":"Kourlaba","year":"2015","journal-title":"BMC Health Serv. Res."},{"issue":"9","key":"10.1016\/j.ijcard.2016.02.140_bb0135","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10198-013-0534-8","article-title":"Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain","volume":"15","author":"Hidalgo-Vega","year":"2014","journal-title":"Eur. J. Health Econ."},{"issue":"3","key":"10.1016\/j.ijcard.2016.02.140_bb0140","first-page":"141","article-title":"Una valutazione economica di ranolazina add-on nel trattamento dell angina stabile cronic","volume":"11","author":"Lucioni","year":"2009","journal-title":"Econ. Ital. Res. Art"},{"issue":"8","key":"10.1016\/j.ijcard.2016.02.140_bb0145","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjcard.2014.01.407","article-title":"Cost-effectiveness of ranolazine added to standard-of-care treatment in patients with chronic stable angina pectoris","volume":"113","author":"Kohn","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2016.02.140_bb0150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.clinthera.2012.04.025","article-title":"Costs and clinical outcomes associated with use of ranolazine for treatment of angina","volume":"34","author":"Phelps","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2016.02.140_bb0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1477-7525-8-54","article-title":"Mapping of the EQ-5D index from clinical outcome measures and demographic variables in patients with coronary heart disease","volume":"8","author":"Goldsmith","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"issue":"4","key":"10.1016\/j.ijcard.2016.02.140_bb0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10198-005-0309-y","article-title":"Estimating utility data from clinical indicators for patients with stable angina","volume":"6","author":"Longworth","year":"2005","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"10.1016\/j.ijcard.2016.02.140_bb0165","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12913-015-1228-y","article-title":"Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study","volume":"15(1)","author":"Kourlaba","year":"2015","journal-title":"BMC Health Serv. Res."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316303825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316303825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T22:04:39Z","timestamp":1654466679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316303825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":33,"alternative-id":["S0167527316303825"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.140","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}